Search company, investor...

Walnut Technologies

Founded Year



Acquired | Acquired

Total Raised


About Walnut Technologies

Non-invasive therapeutic ultrasound devices used to accelerate drug delivery and deliver perfusion therapy for stroke and peripheral thrombosis. Acquired privately in 2003.

Headquarters Location

300 Brickstone Square

Andover, Massachusetts, 01810,

United States


Missing: Walnut Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Walnut Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Walnut Technologies Frequently Asked Questions (FAQ)

  • When was Walnut Technologies founded?

    Walnut Technologies was founded in 1999.

  • Where is Walnut Technologies's headquarters?

    Walnut Technologies's headquarters is located at 300 Brickstone Square, Andover.

  • What is Walnut Technologies's latest funding round?

    Walnut Technologies's latest funding round is Acquired.

  • How much did Walnut Technologies raise?

    Walnut Technologies raised a total of $9.3M.

  • Who are the investors of Walnut Technologies?

    Investors of Walnut Technologies include Garrett Capital, Spray Venture Partners, EW Healthcare Partners, ONSET Ventures, One Equity Partners and 3 more.

  • Who are Walnut Technologies's competitors?

    Competitors of Walnut Technologies include PharmaJet, Erydel, Corium International, NanoPass Technologies, Carbylan Therapeutics and 16 more.

Compare Walnut Technologies to Competitors


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

Global Protein Products

Global Protein Products (GPP) is a zein protein coatings company. Zein protein is the storage protein in corn kernels. It has excellent film-forming and thermoplastic characteristics.


Medi-Stream Pty Limited designs, develops and commercializes drug delivery technologies and devices focused on "˜Air Stream Medication'. The first commercial product released to the market is an Asthma medication delivery device, which has been soft launched to pharmacies under the trade name of Sportshaler. Innovation Capital committed to a $2.5m investment in April 2008.


BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.